Print Page  Close Window


Investor Home


Could not find file '\\aws.nasdaqomx.com\irweb\content3\IRXMLDATA\18\187883\Events2.xml'.

XenoPort is focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended-Release Tablets is approved in the United States. GlaxoSmithKline holds commercialization rights and certain development rights for Horizant in the United States. Regnite® (gabapentin enacarbil) Extended-Release Tablets is approved in Japan. Astellas Pharma Inc. holds all development and commercialization rights for Regnite in Japan and five other Asian countries. XenoPort's pipeline of product candidates includes potential treatments for patients with spasticity, Parkinson's disease and relapsing-remitting multiple sclerosis.

Could not find file '\\aws.nasdaqomx.com\irweb\content3\IRXMLDATA\18\187883\NewsReleaseBlurbs.xml'.

Could not find file '\\aws.nasdaqomx.com\irweb\content3\IRXMLDATA\18\187883\Quotes.xml'.
Could not find file '\\aws.nasdaqomx.com\irweb\content3\IRXMLDATA\18\187883\Quotes.xml'.